Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.
Press releases published on August 1, 2025

Carlsmed’s aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures
CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule …

AI/R Accelerates Personalization at Scale Through Webjump’s Latest Adobe Milestone
Webjump’s fifth Adobe specialization underscores its commitment to innovation and digital excellence as a Platinum Specialized Partner. SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- AI/R, the AI Revolution Company, today announced that its subsidiary, …

AI/R Acelera Personalização em Escala com o Último Marco em Adobe da Webjump
Quinta especialização em Adobe da Webjump ressalta seu compromisso com a inovação e a excelência digital como Platinum Specialized Partner. SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- A AI/R, a AI Revolution Company, anunciou hoje que sua subsidiária, …

Lunar Outpost and the LEGO Group Team Up for Out-Of-This World LEGO® Technic Set
GOLDEN, Colo., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Lunar Outpost, a pioneer in planetary mobility and space resource utilization, and the LEGO Group have debuted the LEGO® Technic Lunar Outpost® Moon Rover Space Vehicle set. The out-of-this-world …

SecureTech Announces Uplisting to OTCQB Venture Market
Roseville, Minnesota, Aug. 01, 2025 (GLOBE NEWSWIRE) -- SecureTech Innovations, Inc. (OTCQB: SCTH), a pioneering technology company advancing artificial intelligence, industrial 3D printing and manufacturing technologies, cybersecurity, and digital …

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion Arm …

NordVPN launches Scam Call Protection feature for Android users in the US
LONDON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Cybersecurity company NordVPN is rolling out a Scam Call Protection feature for Android users in the United States, giving people a new way to spot and dodge fraudulent calls and stay one step ahead of …

Ocugen Provides Business Update with Second Quarter 2025 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trial Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial and on track for 2026 BLA filing OrthoCellix reverse …

OrthoPediatrics Corp. Launches 3P™ Pediatric Plating Platform™ Hip System and Completes First Case
WARSAW, Ind., Aug. 01, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the US launch and first surgical case …

Bridger Aerospace Announces Schedule for its Second Quarter 2025 Earnings Release and Conference Call
BELGRADE, Mont., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced that it will release financial …

I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an …

Travel eSIM app Saily debuts Ultra, a new premium plan for unparalleled journeys
LONDON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NordVPN’s travel eSIM app Saily is launching a premium subscription plan, Saily Ultra, which offers unlimited global eSIM data combined with special benefits for travelers. “The Saily Ultra plan is designed for …

Ascentage Pharma to Participate in Evercore China Biotech Summit
ROCKVILLE, Md. and SUZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in …

Orchestra BioMed Announces Pricing of $40 Million Public Offering
NEW HOPE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced …

FOXO TECHNOLOGIES INC.’S BIG SOUTH FORK MEDICAL CENTER COMPLETES PERFORMANCE NETWORK AGREEMENT WITH COVENANT HEALTH TO PROVIDE SWING BED SERVICES
WEST PALM BEACH, FLORIDA, Aug. 01, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its critical access designated rural hospital, Big South Fork Medical Center located in Oneida, …

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “Company”) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with …

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
SAN DIEGO and TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF; OTCQB: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy …

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on August 1, 2025, it awarded …

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule …

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for …